Cipla Limited

5%

focused markets Revenue (YoY Growth) EBITDA Margin R&D Spends2 Global Cipla Global Ex-Covid 5% 11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid)

11%

sed markets Revenue (YoY Growth) EBITDA Margin R&D Spends2 Global Cipla Global Ex-Covid 5% 11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid) 13%

22%

Revenue (YoY Growth) EBITDA Margin R&D Spends2 Global Cipla Global Ex-Covid 5% 11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid) 13% (YoY Growth)

23%

) EBITDA Margin R&D Spends2 Global Cipla Global Ex-Covid 5% 11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid) 13% (YoY Growth) Chronic Share Spec

6%

TDA Margin R&D Spends2 Global Cipla Global Ex-Covid 5% 11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid) 13% (YoY Growth) Chronic Share Specialty

20%

Spends2 Global Cipla Global Ex-Covid 5% 11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid) 13% (YoY Growth) Chronic Share Specialty In- Licensed Co

13%

11% Global 22% Adj. margin1 ~23% ~6% of Revenue 20% (YoY) One-India Revenue (Ex-Covid) 13% (YoY Growth) Chronic Share Specialty In- Licensed Consumer Franchise3 300bps 44% 24% North

300bps

Revenue (Ex-Covid) 13% (YoY Growth) Chronic Share Specialty In- Licensed Consumer Franchise3 300bps 44% 24% North America $733Mn 23% (YoY Growth) largest by prescription4 in US Generics for R

44%

(Ex-Covid) 13% (YoY Growth) Chronic Share Specialty In- Licensed Consumer Franchise3 300bps 44% 24% North America $733Mn 23% (YoY Growth) largest by prescription4 in US Generics for Respir

24%

Covid) 13% (YoY Growth) Chronic Share Specialty In- Licensed Consumer Franchise3 300bps 44% 24% North America $733Mn 23% (YoY Growth) largest by prescription4 in US Generics for Respiratory

2%

Y Growth) largest by prescription4 in US Generics for Respiratory 3rd South Africa SA Private 2% (YoY ZAR) 3 Yr CAGR - 8.9% vs market growth - 4.4% International Markets $376Mn Double digit

8.9%

iption4 in US Generics for Respiratory 3rd South Africa SA Private 2% (YoY ZAR) 3 Yr CAGR - 8.9% vs market growth - 4.4% International Markets $376Mn Double digit in-market growth across key

Registered Office

1

Registered Office

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ajinkya Pandharkar Investor.Relations@cipla.com For more information please visit www.cipla.com 21